Are Kava Extracts Safe? What the Evidence Says

A persistent position in the kava community holds that extracts are the problem: that traditional water-prepared root is safe because three thousand years of Pacific use says so, and that concentrated extracts caused the liver injury reports that got kava banned across much of Europe in the early 2000s. It is a coherent argument, it is held sincerely by people who know kava well, and it is not entirely wrong.

It is also not the conclusion the evidence best supports. This article walks through what actually happened, what the case reports implicated when they were examined closely, and what a buyer should require of an extract supplier as a result.

We manufacture kava extracts, so we have an obvious interest here. We have tried to write this so that a reader who disagrees with our conclusion can still check our reasoning against the sources.

What Happened, 1998–2002

Between 1998 and 2002, European regulators accumulated case reports of hepatotoxicity — liver injury ranging from raised enzymes to fulminant failure requiring transplant — in people using kava preparations. The commonly cited figure is around 70 to 80 reports across Germany and Switzerland.

The regulatory response was rapid. Germany's BfArM revoked marketing authorisations for kava products in 2002. Switzerland, France and the United Kingdom took comparable action. The US FDA issued a consumer advisory in 2002 warning of a potential risk of severe liver injury, which remains in place. Kava went from a growing European phytomedicine category to effectively banned in the space of about a year.

For Pacific Island producing nations this was economically severe, and it is the origin of a great deal of the caution that still surrounds the category.

What the Case Reports Actually Contained

The reports were assessed repeatedly over the following two decades, and the picture that emerged was considerably messier than "kava causes liver injury".

Rolf Teschke and colleagues applied structured causality assessment — the RUCAM method used to attribute drug-induced liver injury — to the original case series. Their published analyses concluded that a large proportion of the reports contained significant confounding: concurrent hepatotoxic medications, alcohol use, pre-existing liver disease, dosing well beyond recommended levels, or use over durations far exceeding label instructions. In a substantial share of cases the documentation was insufficient to establish causality at all. A small number of cases remained where kava was a plausible cause.

This does not mean the reports were meaningless. It means the effect, if attributable to kava, was rarer than the headline count implied, and that the case series could not by itself identify what about kava was responsible.

That question — which kava, and why — is where the useful work happened.

The Raw Material Hypothesis

Two findings about raw material quality emerged in the years after the bans, and both point away from concentration as the mechanism.

Aerial parts and pipermethystine

Traditional Pacific preparation uses the root and rhizome. The aerial parts of the plant — stems, stem peelings, leaves — are not used, and in kava-growing cultures this is well understood.

In 2003, Dragull, Yoshida and Tang identified pipermethystine, an alkaloid present in the leaves and stem peelings of Piper methysticum but essentially absent from the root. Subsequent in vitro work demonstrated cytotoxic effects on hepatocytes. Vincent Lebot and others documented that during the demand surge of the late 1990s, some material entering the export chain included stem peelings and other aerial material — a way to increase yield from a crop that suddenly could not be grown fast enough.

The timing is suggestive. The European case reports cluster in exactly the period when demand pressure was highest and raw material discipline was most likely to have slipped.

Non-noble cultivars and flavokavain B

Kava cultivars divide into noble varieties, selected over centuries of Pacific cultivation for daily consumption, and non-noble varieties — tudei, Isa, and wild Piper wichmannii types — which are faster growing, higher yielding, and traditionally avoided for regular use.

Non-noble cultivars carry higher concentrations of flavokavains, particularly flavokavain B, which has demonstrated cytotoxicity in laboratory studies and has been proposed as a contributor to hepatic stress, potentially via glutathione depletion. The same demand pressure that pulled aerial parts into the supply chain also pulled non-noble material in, for the same reason: it was available and it was cheaper.

Both Fiji and Vanuatu have since legislated noble-only export requirements — Vanuatu through its Kava Act and Fiji through the Kava Bill (2022) — precisely because cultivar identity was identified as a control point. See noble vs. non-noble kava for the full distinction.

The Solvent Hypothesis

The second line of explanation concerns how the extract was made, and this is where the "extracts are the problem" position has its strongest footing.

Traditional preparation is aqueous. Kavalactones are poorly water-soluble, so kneading root powder in cold water produces an emulsion that carries a fraction of the plant's kavalactone load — and leaves a great deal behind, along with most of the compounds that water does not mobilise.

The European pharmaceutical preparations implicated in the case reports were largely acetone or ethanol extracts. Organic solvents extract more efficiently and less selectively. They pull across lipophilic constituents that aqueous preparation leaves in the plant material, and they concentrate them.

The WHO's 2007 assessment of the risk of hepatotoxicity with kava products reflected this distinction, drawing a line between aqueous preparations with a comparatively reassuring safety record and organic-solvent extracts where the concerns were concentrated. The Codex Alimentarius regional standard adopted in 2020 for kava as a beverage mixed with water takes the same approach from the other direction: it specifies noble cultivars, root and rhizome only, and excludes aerial parts.

So the distinction that matters is not concentrated versus dilute. It is which compounds the extraction method carries across, and what raw material it started from.

Why "Extracts Are the Problem" Is the Wrong Generalisation

Putting the two hypotheses together produces a more precise statement than either the pro- or anti-extract position usually offers.

The preparations associated with the European case reports were, in many instances, organic-solvent extracts of raw material whose cultivar and plant-part provenance was not verified, produced during a period of acute supply pressure, consumed by people frequently taking other hepatotoxic substances. Each of those is a variable. Concentration is one of them, and it is the one for which the mechanistic evidence is weakest.

The argument that extracts as a class are unsafe requires concentration to be doing the causal work. If instead the mechanism runs through pipermethystine from aerial parts and flavokavain B from non-noble cultivars, then a concentrated extract of verified noble root is a different proposition from a concentrated extract of unverified material — and a water-prepared beverage made from unverified material is not automatically safe either.

That last point is worth dwelling on, because it cuts against a comfortable assumption. Traditional preparation method does not confer safety on non-noble raw material. Tudei consumed as a traditional beverage is still tudei.

Where the Regulatory Position Stands Now

The regulatory picture has moved, unevenly.

In 2014 the Administrative Court of Cologne overturned Germany's ban, finding the regulatory action disproportionate to the evidence — a decision that went through further legal process thereafter. Kava has been available in Germany under prescription-medicine conditions in the period since. Poland, Austria and several other European states have moved at their own pace, and the EU remains a member-state patchwork rather than a single position.

In the United States, kava is marketed as a dietary supplement under DSHEA. The FDA's 2002 consumer advisory has not been withdrawn, and it remains the operative federal signal.

Australia and New Zealand regulate kava under FSANZ Standard 1.4.4, which permits kava as a food in water-based preparations — Australia's 2021 commercial import framework reflects exactly the aqueous-versus-solvent distinction described above.

The direction of travel over twenty years has been toward regulating on raw material and preparation method rather than banning the plant. That is the correct read of the evidence, and it is the framework a buyer should be working within.

What This Means for a Buyer

If the mechanism runs through raw material and solvent rather than concentration, then the controls are specific and verifiable. These are the things to require in writing, for any kava material and particularly for any extract:

1. Cultivar verification. Noble-only sourcing, evidenced by chemotype on the batch certificate. Noble cultivars show a kavalactone dominance pattern beginning 42 or 24. See how to read a kava chemotype.
2. Plant part specification. Root and rhizome only, aerial parts explicitly excluded, stated in the specification rather than assumed.
3. Extraction solvent disclosed. Supercritical CO₂, ethanol, acetone, or aqueous — named, not described as "proprietary".
4. Residual solvent testing per USP <467>. Class I, II and III, reported with measured values against limits. This is the direct check on the solvent question and it is non-negotiable for any extract format.
5. Full HPLC kavalactone profile. All six kavalactones individually, not a single total.
6. Flavokavain disclosure where relevant. Increasingly requested by buyers building toward the evidence base; a supplier who cannot discuss it is a supplier who has not thought about it.
7. Heavy metals, microbial and pesticide panels. Standard, per batch, against defined limits.

A supplier who can produce all seven for a concentrated extract is offering something materially better characterised than most traditionally-prepared material on the market, which typically arrives with no certificate at all. The supplier vetting checklist covers the full diligence process.

How Kavain's Extracts Are Made

For transparency about our own position in this argument:

• Our oleoresin is produced by supercritical CO₂ extraction. Carbon dioxide is used as the extraction medium and leaves the product as a gas — the process avoids acetone and ethanol entirely.
• Raw material is noble-cultivar root and rhizome from Vanuatu and Fiji, chemotype-verified on intake. No aerial parts.
• Our nano powder and nano liquid are nano-emulsified from that oleoresin at a cGMP-compliant US facility using food-grade sunflower phosphatides and MCT carriers.
• Every batch carries a Certificate of Analysis including HPLC kavalactone profiling, residual solvents per USP <467>, heavy metals, microbial screening and pesticide residues. See our testing scope.

Between them, those four things address every control point the evidence identifies: cultivar, plant part, solvent, and residual solvent verification. The result is a fully characterised material — one where what is in it, and what is not, is documented per batch and available to any buyer who asks.

The Honest Summary

Caution about extracts is understandable, and it comes from a real episode. What that period demonstrated was how much depends on two specific things: the raw material going in, and the method used to get the kavalactones out. Those are precisely the variables the industry has spent the years since learning to specify, test and document.

The inference from "those extracts were implicated" to "extracts are the problem" skips the step where you ask what was in them. When that step is taken, the recurring findings are cultivar, plant part, and solvent — three things that can be specified, tested, and verified — rather than concentration, which cannot be tested for because it is not a defect.

The useful question is not whether to use extracts. It is whether your supplier can tell you what is in theirs, and prove it per batch.

This article discusses safety evidence relevant to commercial sourcing decisions and product specification. It is not medical advice and makes no health claim about any product. Kava's regulatory status differs substantially by market; confirm the requirements for your destination market before formulating or importing. Buyers formulating kava products should seek their own regulatory and toxicological advice.